| Home | E-Submission | Sitemap | Contact Us |  
Cancer Research and Treatment > Volume 33(6); 2001 > Article
Cancer Research and Treatment 2001;33(6): 489-494. doi: https://doi.org/10.4143/crt.2001.33.6.489
Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregional Esophageal Cancer
Gyeong Won Lee, Jung Hun Kang, Hun Gu Kim, In Gyu Hwang, Ki Shik Shim, Seok Hyun Kim, Won Sep Lee, Woon Tae Jung, Ok Jae Lee, Jung Hyeun Cho, Joung Soon Jang, Kyu Yong Chae, Jong Seok Lee
1Department of Internal Medicine, College of Medicine,Gyeong-Sang National University, Jinju, Korea.Jonglee@nongae. gsnu.ac.kr
2Department of Therapeutic Radiology, College of Medicine,Gyeong-Sang National University, Jinju, Korea.
3Department of Cancer Research Center, College of Medicine,Gyeong-Sang National University, Jinju, Korea.
  Published online: December 31, 2001.
The object of this study is to evaluate the efficacy and toxicity of induction chemotherapy followed by concomitant chemoradiotherapy in locoregional esophageal cancer.
Between December 1992 and December 1999, 43 patients with locoregional esophageal cancer were enrolled in this phase II trial. Patients were treated with 2-cycles of induction chemotherapy followed by concomitant chemoradiotherapy. F-P chemotherapy consists of 1,000 mg/m2/Day of 5-FU as continuous infusion on day 1~5 and 80 mg/m2 of cisplatin as an intravenous bolus on day 1 and was repeated every 3~4 weeks. All patients received 60 Gy of external beam radiation concomitantly with F-P chemotherapy; intraluminal brachytherapy was added in 12 patients. A total of 4 cycles of chemotherapy were delivered. No further treatment was planned in patients who achieved complete remission after completion of the treatment.
Among the 43 patients entered, 35 patients completed the protocol. Of the 35 evaluable patients, 12 patients (34%) achieved complete response and 13 patients (37%) achieved partial response. In 26 of 33 patients, dysphagia was improved. At a median follow-up of 22 months, the 2-year and 5-year survival rates were 39% and 19%, respectively. The median survival duration of the complete responder group was 69 months (4~100 months) and the 2-year survival rate of the complete responder group was 82%. Toxicities were tolerable, comprised of mucositis and cytopenia.
Induction chemotherapy followed by concurrent chemoradiotherapy in locoregional esophageal cancer is well tolerated and effective.
Key words: Esophageal neoplasm;Induction chemotherapy;Concurrent chemoradiotherapy
Editorial Office
Korean Cancer Association
Room 1824, Gwanghwamun Officia
92 Saemunan-ro, Jongno-gu, Seoul 03186, Korea
TEL: +82-2-3276-2410   FAX: +82-2-792-1410   E-mail: journal@cancer.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © Korean Cancer Association.                 Developed in M2PI